Abraham Zachary Cheloff

Dr. Abraham Zachary Cheloff

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
ACAbraham Zachary Cheloff
Abraham Zachary Cheloff
HAHanny Al-Samkari
Hanny Al-Samkari
Avatrombopag is an orally-administered small molecule thrombopoietin receptor agonist. It was the third thrombopoietin receptor agonist approved for the treatment of immune thrombocytopenia and the first approved to treat periprocedural thrombocytopenia in patients with chronic liver disease (thereby providing an alternative to blood transfusions for these patients). Unlike eltrombopag, avatrombopag does not require a 4 hr food-restricted window around its use and it has not been associated with hepatotoxicity in ITP patients or portal vein thrombosis in patients with chronic liver disease. In ITP patients it can often be dosed less frequently than once daily. It is overall well-tolerated with a side-effect profile similar to placebo in randomized clinical trials. This article will review the clinical development, efficacy, safety, and pharmacology of avatrombopag for use in patients with ITP and thrombocytopenia of chronic liver disease.

21 June 2020 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
ACAbraham Zachary Cheloff
Abraham Zachary Cheloff
DKDavid J. Kuter
David J. Kuter
HAHanny Al-Samkari
Hanny Al-Samkari
Background Complement may contribute to platelet destruction in immune thrombocytopenia (ITP), but serum complement levels of ITP patients are not well defined. This study characterized C3, C4, and CH50 levels from 108 ITP patients in comparison with 120 healthy subjects. Methods Results of complement testing performed using commercially available turbidimetric immunoassays were retrospectively analyzed. Mean complement levels in patients with ITP were compared with levels from a sample of 120 healthy subjects, and subgroups of ITP patients were compared. Regression analyses evaluated for relations between low complement levels and disease severity and response to ITP treatments. Results One hundred eight patients with ITP were included. Mean C3, C4, and CH50 were significantly lower in patients with ITP compared with healthy subjects, largely driven by the 32% of patients with ITP with substantial reductions in one or more assays. Patients requiring treatment had lower mean C4 (18.1 vs 23.1 mg/dL; P = .042) and CH50 (50.4 vs 63.0 mg/dL; P = .004). Mean C3 was higher in splenectomized versus nonsplenectomized patients (120.6 vs 101.0 mg/dL; P = .035). In multivariable analyses, reduced complement did not predict treatment response to corticosteroids, intravenous immunoglobulin, or thrombopoietin receptor agonists but low C4 levels did predict more severe ITP (relative to nonsevere disease, odds ratio for severe/refractory disease: 6.28; 95% confidence interval, 0.75‐52.54; P = .090). Complement levels in patients with ITP were generally consistent over repeat measurements. Conclusions Complement levels are reduced in one‐third of patients with ITP and are associated with more severe disease. Additional study is needed to evaluate if hypocomplementemia is predictive of response to emerging complement‐directed therapies.

1 January 2020 in Drugs of Today
Verified
Journal Article
Closed access
ACAbraham Zachary Cheloff
Abraham Zachary Cheloff
HAHanny Al-Samkari
Hanny Al-Samkari
Emapalumab-Igsz (Gamifant) is a human monoclonal antibody directed against interferon-γ (IFN-γ), and the first Food and Drug Administration (FDA)-approved therapy for primary hemophagocytic lymphohistiocytosis (HLH). HLH is a disorder characterized by hypercytokinemia in the setting of unbridled immune activation, and emapalumab represents the first therapeutic developed to address the underlying pathophysiology of HLH. Emapalumab is approved for treatment of primary HLH that is refractory, recurrent, progressing or intolerant to current HLH treatments in both adult and pediatric patients. FDA approval was based on the results of a phase II/III clinical trial evaluating the safety and efficacy of emapalumab in 34 pediatric patients with primary HLH, 27 of whom were refractory to current therapies. Additional studies of emapalumab are currently ongoing in adults and other pediatric populations. Here, we will review the pharmacology, safety and efficacy of emapalumab for the treatment of HLH.

2 February 2018 in Biochemistry
Verified
Journal Article
Closed access
DTDaniel L. Turman
Daniel L. Turman
ACAbraham Zachary Cheloff
Abraham Zachary Cheloff
ACAlexis D. Corrado
Alexis D. Corrado
JNJacob T. Nathanson
Jacob T. Nathanson
CMChristopher Miller
Christopher Miller

28 February 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
ACAbraham Zachary Cheloff
Abraham Zachary Cheloff
LKLeah Kim
Leah Kim
MPMark B. Pochapin
Mark B. Pochapin
ASAasma Shaukat
Aasma Shaukat
VPVioleta Popov
Violeta Popov
INTRODUCTION: Measurement of colorectal polyps is typically performed through visual estimation, which is prone to bias. Studies have evaluated the accuracy of visual estimation and utility of assistive tools, but results have been mixed. The aim of this study was to clarify the accuracy of visual estimation as a measurement tool and the benefits of artificial intelligence. METHODS: MEDLINE and Embase were searched through October 2024. Extraction and quality assessment were performed independently by 2 authors. The primary outcome was the pooled absolute mean difference in size between visual estimation and control. Secondary outcomes included subgroup analysis of expert vs trainee status, accuracy of artificial intelligence, study origin (East vs West), comparator type, definition of accuracy, polyp size, direction of estimation, and image type. RESULTS: Thirty-five studies with 42,964 polyp measurements were included in our analysis. All studies were of high quality, and there was no evidence of publication bias. The pooled absolute mean difference from comparator was 1.68 mm (confidence interval 1.21–2.15) with high variability explained by differences in the comparator, direction of estimation, image type, and size of the polyp. Overall accuracy was 60% with high variability as well, with increased accuracy with video displayed over photographs. Artificial intelligence improved accuracy with an odds ratio of 7.46. DISCUSSION: Visual estimation is an inaccurate and imprecise way to measure colorectal polyps. Further research is needed to determine the impact on clinical outcomes related to colorectal cancer. Investment in new technology to aid in polyp measurement is an important next step.

1 September 2022 in Platelets
Verified
Journal Article
Closed access
ACAbraham Zachary Cheloff
Abraham Zachary Cheloff
HAHanny Al-Samkari
Hanny Al-Samkari
TO THE EDITOR:PARP (poly-adenosine diphosphate-ribose polymerase) inhibitors are a series of drugs designed to inhibit DNA repair mechanisms, preventing DNA repair in cancer cells and inducing cell...